Theoretically, it is possible to use multiple CARs to target multiple antigens; however, it is not easy to find an almost ideal surface antigen like CD19 that can be safely targeted without causing serious unmanageable on-target off-cancer side effect, not to mention finding multiple such antigens. This evidence concerns the gene CD19 and cancer.